Cargando…

Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?

BACKGROUND: Genetic make up had been known to influence pharmacokinetics and pharmacodynamics of psychotropic medications. Time separation in evolutionary trend in Africans, Orientals and Caucasians had been thought a possible explanation for the observed racial variation in activities of Cytochrome...

Descripción completa

Detalles Bibliográficos
Autor principal: Bakare, Muideen O
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518282/
https://www.ncbi.nlm.nih.gov/pubmed/18710544
http://dx.doi.org/10.1186/1756-0500-1-25
_version_ 1782158556821192704
author Bakare, Muideen O
author_facet Bakare, Muideen O
author_sort Bakare, Muideen O
collection PubMed
description BACKGROUND: Genetic make up had been known to influence pharmacokinetics and pharmacodynamics of psychotropic medications. Time separation in evolutionary trend in Africans, Orientals and Caucasians had been thought a possible explanation for the observed racial variation in activities of Cytochrome P 450 (CYP 450) enzymes, which are responsible for metabolism of psychotropic and other medications in human. Past studies on pharmacokinetics and pharmacodynamics of antipsychotic medications and socio-cultural factors influencing response to antipsychotic medications had consistently giving an inkling of possible racial difference in symptoms response to antipsychotic medications. Another growing body of evidence subscribing to possible racial difference in psychotic symptoms response to antipsychotic medications is the observed variation in antipsychotic medications prescription pattern and dosage across races and regions. Empirical observation had shown that dosage prescription pattern of antipsychotic medications in most Sub-Saharan African countries deviates from the standard prescription guidelines published for use in western parts of the world. Studies coming from the United States (U.S) had consistently reported a higher dosage of antipsychotic medications prescription for African-American patients compared to their Caucasian counterparts. Research on East Asia Psychotropic Prescription (REAP) study had also identified high dosage antipsychotic medications prescription pattern well above the recommended dose of 1,000 mg Chlorpromazine equivalent per day as common practices in some East Asian countries. PRESENTATION OF THE HYPOTHESIS: The pertinent question is why the apparent differences in dosage prescription practices across races and regions? The possibility of racial differences in psychotic symptoms response to antipsychotic medications rather than clinicians' prescription attitudes was entertained. TESTING THE HYPOTHESIS: Future carefully controlled studies might be needed to test the proposed hypothesis of racial differences in psychotic symptoms response to antipsychotic medications. IMPLICATION OF THE HYPOTHESIS: There might be actual racial influence on psychotic symptoms response to antipsychotic medications. If future carefully controlled studies uphold the hypothesis of racial differences in psychotic symptoms response to antipsychotic medications, there might be need to draw up new treatment or prescription guidelines that would put into consideration variations in genetic make up and consequent racial differences in psychotic symptoms response to antipsychotic medications.
format Text
id pubmed-2518282
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25182822008-08-21 Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference? Bakare, Muideen O BMC Res Notes Hypothesis BACKGROUND: Genetic make up had been known to influence pharmacokinetics and pharmacodynamics of psychotropic medications. Time separation in evolutionary trend in Africans, Orientals and Caucasians had been thought a possible explanation for the observed racial variation in activities of Cytochrome P 450 (CYP 450) enzymes, which are responsible for metabolism of psychotropic and other medications in human. Past studies on pharmacokinetics and pharmacodynamics of antipsychotic medications and socio-cultural factors influencing response to antipsychotic medications had consistently giving an inkling of possible racial difference in symptoms response to antipsychotic medications. Another growing body of evidence subscribing to possible racial difference in psychotic symptoms response to antipsychotic medications is the observed variation in antipsychotic medications prescription pattern and dosage across races and regions. Empirical observation had shown that dosage prescription pattern of antipsychotic medications in most Sub-Saharan African countries deviates from the standard prescription guidelines published for use in western parts of the world. Studies coming from the United States (U.S) had consistently reported a higher dosage of antipsychotic medications prescription for African-American patients compared to their Caucasian counterparts. Research on East Asia Psychotropic Prescription (REAP) study had also identified high dosage antipsychotic medications prescription pattern well above the recommended dose of 1,000 mg Chlorpromazine equivalent per day as common practices in some East Asian countries. PRESENTATION OF THE HYPOTHESIS: The pertinent question is why the apparent differences in dosage prescription practices across races and regions? The possibility of racial differences in psychotic symptoms response to antipsychotic medications rather than clinicians' prescription attitudes was entertained. TESTING THE HYPOTHESIS: Future carefully controlled studies might be needed to test the proposed hypothesis of racial differences in psychotic symptoms response to antipsychotic medications. IMPLICATION OF THE HYPOTHESIS: There might be actual racial influence on psychotic symptoms response to antipsychotic medications. If future carefully controlled studies uphold the hypothesis of racial differences in psychotic symptoms response to antipsychotic medications, there might be need to draw up new treatment or prescription guidelines that would put into consideration variations in genetic make up and consequent racial differences in psychotic symptoms response to antipsychotic medications. BioMed Central 2008-06-12 /pmc/articles/PMC2518282/ /pubmed/18710544 http://dx.doi.org/10.1186/1756-0500-1-25 Text en Copyright © 2008 Bakare; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hypothesis
Bakare, Muideen O
Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title_full Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title_fullStr Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title_full_unstemmed Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title_short Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?
title_sort effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference?
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518282/
https://www.ncbi.nlm.nih.gov/pubmed/18710544
http://dx.doi.org/10.1186/1756-0500-1-25
work_keys_str_mv AT bakaremuideeno effectivetherapeuticdosageofantipsychoticmedicationsinpatientswithpsychoticsymptomsistherearacialdifference